Open AccessAnti‐ VEGF ‐A/ ANG 2 combotherapy limits pathological angiogenesis in the eye: a replication study
Author(s) -
Wolf Anne,
Langmann Thomas
Publication year - 2019
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.201910362
Subject(s) - ophthalmology , medicine , library science , computer science
Neovascular and inflammatory retinal diseases including wet age‐related macular degeneration ( AMD ) can cause severe vision loss among the elderly. Simultaneous neutralization of vascular endothelial growth factor‐A ( VEGF ‐A) and angiopoietin 2 ( ANG 2) is envisioned as a novel candidate approach to treat wet AMD with better efficacy. However, earlier published data from a genetic mouse model showed data aberrations (Regula et al , 2016). In this issue of EMBO Molecular Medicine , Foxton et al (2019) have provided compelling evidence replicating the data and confirming the overall concept that VEGF ‐A/ ANG 2 combotherapy is effective in suppressing retinal neovascularization.